Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 4, 2015

View Archived Issues

Regen Bio develops depot local delivery of CTCFL-targeting siRNA for liver cancer

Ocata receives NIH grant to develop photoreceptor cell therapy for retinal degenerative diseases

Adaptimmune expands phase I/II trial of NY-ESO TCR therapeutic in synovial sarcoma

MediWound completes enrollment in second phase II trial of EscharEx

Janssen discloses new GPR120 agonists for diabetes

MicroRNA panel may allow earlier diagnosis of pancreatic cancer

Innocoll initiates first phase III trial of XaraColl

Daiichi Sankyo licenses Japanese rights to MedImmune's FluMist Quadrivalent

Bristol-Myers Squibb discloses new gamma-secretase modulators for AD

Vaxin changes name to Altimmune

Sandoz launches the first biosimilar in the U.S.

Acadia submits NDA for Nuplazid for Parkinson's disease psychosis

GSK discloses IFN-alpha inducers

Bayer presents novel dual sGC activators and PDE5 inhibitors

Takeda patents OX1 receptor antagonists

Bristol-Myers Squibb presents macrocyclic HIV integrase inhibitors

Frost Biologic discloses new antimitotics

First launch planned for Acoalan in Japan

FDA grants breakthrough therapy designation to ACE-910 for hemophilia A

Tetraphase's TP-271 receives FDA QIDP and fast track designations

FDA accepts sBLA filing for Opdivo in previously treated non-squamous NSCLC

Merck & Co. divulges A2A receptor antagonists

Sanofi terminates option to license Ardelyx's RDX-002 program

Cure Duchenne provides funds to MyoTherix to advance promising DMD research

Remestemcel-L recommended for approval in Japan

Amgen reports new BACE1 inhibitors for the treatment of AD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...